Novel Sirolimus-Coated Balloon Catheter: In Vivo Evaluation in a Porcine Coronary Model.
Yvonne Patricia Clever, Daniel Peters, Jorge Calisse...
https://pubmed.ncbi.nlm.nih.gov/27069105/Actively Recruiting
Led by Concept Medical Inc. · Updated on 2025-07-03
219
Participants Needed
20
Research Sites
52 weeks
Total Duration
This research aims to evaluate and compare the use of a sirolimus drug coated balloon versus standard balloon angioplasty for treating below the knee arterial disease, a condition linked to peripheral arterial disease PAD that can lead to limb loss. The study addresses concerns about safety with current paclitaxel drug coated balloons and explores sirolimus as a potentially safer alternative with promising early results in coronary arteries. Participants will receive either the MagicTouch PTA sirolimus drug coated balloon after successful plain balloon angioplasty or a placebo balloon angioplasty alongside the standard procedure. The sirolimus balloon is sized according to the initial angioplasty and applied to the lesion. The study is randomized, double-blind, and involves multiple centers. Throughout the trial, participants will be monitored for primary patency at 6 months, along with secondary outcomes including death, limb amputation, vessel thrombosis, adverse events, procedural success, revascularization need, wound healing, and pressure assessments up to 24 months. The research includes detailed follow-ups and safety checks to assess the device and procedure effectiveness over time.
CONDITIONS
SirolimUs CoaTed Balloon for The TrEatment of Below The Knee Arterial Disease
E
Edward Choke
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Concept Medical Inc.
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Day 0 (procedure day)
Participants undergo standard balloon angioplasty, followed by randomization to receive either the MagicTouch PTA sirolimus drug coated balloon or a placebo balloon angioplasty at the lesion site.
1 procedure visit (in-person)
Duration - Up to 24 months
Participants are monitored for safety, device and procedure related outcomes, and limb health including assessments of patency, adverse events, and limb amputation status.
Visits at 1, 6, 12, and 24 months for assessments
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Yvonne Patricia Clever, Daniel Peters, Jorge Calisse...
https://pubmed.ncbi.nlm.nih.gov/27069105/Daniele Giacoppo, Salvatore Cassese, Yukinori Harada...
https://pubmed.ncbi.nlm.nih.gov/27539695/Stefan Verheye, Mathias Vrolix, Indulis Kumsars...
https://pubmed.ncbi.nlm.nih.gov/28964764/Concept Medical Inc.
Lead Sponsor